Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03807102

Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer (TVATLC01)

Phase I/II Trial of Tumor Vaccine in Post Radical Operation Patients With Lung Cancer

Sponsor: Shanghai Houchao Biotechnology Co., Ltd

Updated 7 times since 2019 Last updated: Dec 25, 2023 Started: Jan 16, 2024 Primary completion: Jan 31, 2025 Completion: Jan 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Lung Cancer and is currently ongoing. Shanghai Houchao Biotechnology Co., Ltd leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE1/PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Not Yet Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

Status: Unknown Status → Not Yet Recruiting
Mar 2023 — Jan 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Mar 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Feb 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Houchao Biotechnology Co., Ltd
Yongchang Zhang

Data source: Hunan Province Tumor Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changsha, China